Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Oral Voxelotor in Sickle Cell Disease
2017-004045-25Phase 3Unknown
- Sponsor
- Global Blood Therapeutics, Inc.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics, Inc. Primary endpoints: Safety (Adverse Events), Safety (Clinical Laboratory Tests) and 1 more. Status: unknown.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2017-004045-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004045-25.